Fosmax Daily: Merck will retain exclusivity until 2007
May 16, 2002 Introduction. Teva and IVAX’s legal efforts to launch a generic osteoporosis drug to compete with Merck’s Fosamax [...]
Paxil 1: Glaxo’s Patents Appear Safe Until at least 2006
January 31, 2002 INTRODUCTION Although there has been one $8 million verdict in a personal injury case involving Paxil, it [...]
Paxil 2: Invalidation of UK patents will not impact US cases
August 14, 2002 Introduction. On July 12, 2002, in a revocation proceeding brought by BASF, the British patent court invalidated [...]
Taxol 1: Why did ABI to list 331 in the Orange Book?
April 20, 2000 Background: In April 2000, Ivax won a court order invalidating Bristol Myers Squibb’s (BMY) patent protection on [...]
Taxol 2: Can Ivax to launch its generic Taxol?
September 18, 2000 On Thursday, the Ninth Circuit refused to grant BMY’s Request for stay: if granted it would have [...]
Taxol 3: Has Bristol Myers cut a deal with Napro?
November 2, 2000 Napro’s suit against Bristol Myers Squibb over Taxol offers both companies a way to block the sale [...]
Taxol 4: Can FDA issue ANDAs to Mylan & Zenith
April 16, 2001 Ivax’s 180 day marketing exclusivity on paclitaxel expires on April 21, 2001 On March 30, 2001, the [...]
Taxol 5: NaPro and Abbot sue Mylan
June 13, 2001 I – Introduction: The short complaint filed yesterday by NaPro and Abbot against Mylan in Federal court [...]
Related Case Type
